Compare PHR & OABI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PHR | OABI |
|---|---|---|
| Founded | 2005 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 788.3M | 696.4M |
| IPO Year | 2019 | 2021 |
| Metric | PHR | OABI |
|---|---|---|
| Price | $12.58 | $5.11 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 18 | 7 |
| Target Price | ★ $13.93 | $8.33 |
| AVG Volume (30 Days) | 633.2K | ★ 1.4M |
| Earning Date | 12-07-2026 | 10-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 103.92 | 6.56 |
| EPS | ★ 0.08 | N/A |
| Revenue | ★ $480,591,000.00 | $18,666,000.00 |
| Revenue This Year | $7.32 | $94.10 |
| Revenue Next Year | $3.73 | $30.33 |
| P/E Ratio | $155.56 | ★ N/A |
| Revenue Growth | ★ 14.48 | N/A |
| 52 Week Low | $7.77 | $1.32 |
| 52 Week High | $23.31 | $5.43 |
| Indicator | PHR | OABI |
|---|---|---|
| Relative Strength Index (RSI) | 69.00 | 56.98 |
| Support Level | $11.38 | $4.51 |
| Resistance Level | $12.70 | $5.06 |
| Average True Range (ATR) | 0.47 | 0.34 |
| MACD | 0.09 | 0.02 |
| Stochastic Oscillator | 89.79 | 64.93 |
Phreesia Inc is a provides an integrated software, payments, and engagement platform designed to address three foundational challenges in healthcare delivery: access to care, affordability of care, and patient health outcomes. Its platform is embedded directly into provider workflows and patient interactions, enabling healthcare organizations to activate patients, streamline administrative processes, and improve financial performance across the care continuum. The group serves a diverse group of healthcare organizations, including ambulatory practices, health systems, and hospitals, as well as life sciences companies, government entities, patient advocacy, public interest, and not-for-profit and other organizations.
OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.